Project Grant R43HL162270

Award Date 9/1/22
Completion Date 8/31/23
Dollars Obligated $326K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02135, USA
Similar Awards
This $256,000 National Science Foundation SBIR Phase I Project Grant to Airomatix, Inc. supports the development of a portable oxygen concentrator capable of producing breathable oxygen at higher flow rates than current models. The concentrator utilizes a novel photocatalytic reaction to separate oxygen from ambient air and store it in a chemical solution. It will then release oxygen on demand through a temperature-controlled reaction. During the one-year period of performance ending March 2023,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $294,063 to Biomembretics, Inc. to develop and demonstrate high-volume manufacturing of a biomimetic microfluidic oxygenator for extracorporeal membrane oxygenation (ECMO) to treat respiratory failure. The project aims to advance a safer and simpler alternative to the current standard of invasive mechanical ventilation, which carries...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $740,196 project grant (R01HL177837) to Case Western Reserve University (CWRU) to investigate the adverse effects of neonatal continuous positive airway pressure (CPAP) on lung development. The project, which will run from June 1, 2025, to March 31, 2029, aims to utilize a mouse model and human fetal airway smooth muscle (FASM) in vitro stretch model to test the hypothesis that stretch-induced effects on airway smooth muscle...
This $773,916 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to develop a tool to calculate the contribution of different phenotypes of bronchopulmonary dysplasia (BPD) to elevated breathing effort in premature neonates. The goal is to create and validate a mechanism to determine how factors like hyperdense lung tissue, hyperinflated airspaces, and airway obstruction individually...
This $371,021 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund the development and validation of a multimodal monitoring system to accurately detect and classify apnea of prematurity (AOP) in newborns. The grant, with an award date of April 9, 2025 and ultimate completion date of February 28, 2027, will be carried out by Makani Science Inc., a minority-owned small business located in...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $866,579 to The Children's Hospital of Philadelphia (CHOP) to evaluate the effectiveness of an "Optimizing Ventilation (OPTI-VENT)" training bundle for improving cardiac arrest outcomes in children. The OPTI-VENT bundle consists of provider education and point-of-care guidance to train...
This $586,021 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to establish patient-reported outcome measures that refine risk stratification and identify barriers to post-discharge specialty care for preterm infants with bronchopulmonary dysplasia (BPD). The goal is to use mobile health strategies to link NICU data to parent-reported outcomes from pre-discharge through...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $306,643 to Mira Medical, LLC to develop a new extracorporeal membrane oxygenation (ECMO) pump designed for efficient low blood flow rates needed to treat pediatric and neonatal patients. The key objectives are to design, develop, and test a low-flow ECMO pump capable of operating at 0.05 to 0.5 L/min (50 to 500 cc/min) to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $842,408 to support the development and evaluation of the Aerosolve Biohelmet. The Aerosolve Biohelmet is a personal negative pressure device designed to rapidly isolate and safely transport patients with highly transmissible respiratory illnesses like COVID-19, influenza, and tuberculosis. The...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a modern Electrical Impedance Tomography (EIT) device for monitoring children in the Intensive Care Unit (ICU). The $299,900 award to Goodlife Inventors LLC will fund efforts to (1) generate initial designs for an advanced lightweight EIT belt and (2) assess the technical feasibility of a miniaturized, easier to use EIT core device. If...

A UNIVERSAL AMBIENT AIR-OXYGEN BLENDER TO TREAT RESPIRATORY DISTRESS IN NEWBORNS - APPROXIMATELY 3 MILLION NEONATAL DEATHS OCCUR ANNUALLY DUE TO PREMATURITY, INTRA-PARTUM RELATED CONDITIONS AND INFECTIONS, WITH RESPIRATORY DISTRESS BEING A SERIOUS CONDITION BEING EXPERIENCED BY THE NEWBORN IN EACH CASE. A COMMON TREATMENT TO TREAT RESPIRATORY DISTRESS IS BY PROVIDING OXYGEN-ENRICHED AIR TO THE NEONATE USING A CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) DEVICE. A COMMON CONFIGURATION OF THESE DEVICES INVOLVES CONNECTING THE DEVICE TO A MEDICAL GRADE OXYGEN AND AIR TANKS UPSTREAM FROM THE NEWBORN TO TITRATE THE OXYGEN CONTENT USING A BLENDER, WHICH ALSO CONTROLS THE FLOW RATE OF THE OXYGEN-ENRICHED AIR. A PRESSURE GENERATING WATER BOTTLE WITH A STRAW IS CONNECTED DOWNSTREAM SO THAT THE NEWBORN EXHALES AGAINST PRESSURE DEFINED BY THE WATER DEPTH TO WHICH THE STRAW IS INSERTED, THUS INFLATING LUNGS AND PROVIDING UNIMPEDED RESPIRATION. THERE ARE TWO LIMITATIONS OF CURRENT COMMERCIAL CPAP DEVICES. FIRST, THEY ARE DESIGNED TO REQUIRE WALL ELECTRICITY TO OPERATE THE SENSORS AND HUMIDIFIER, WHICH PREVENTS TREATMENT DURING PRE-HOSPITAL AND INTRA- HOSPITAL TRANSPORT. SECOND, LACK OF AVAILABILITY OF MEDICAL GRADE AIR ESPECIALLY IN RESOURCE POOR REGIONS WORLDWIDE HAVE LED TO IMPROVISED DEVICES DELIVERING 100% OXYGEN CAUSING SEVERE OXYGEN TOXICITY-RELATED COMPLICATIONS SUCH AS RETINOPATHY OF PREMATURITY AND BRONCHOPULMONARY DYSPLASIA. IN THIS PROPOSAL, WE HYPOTHESIZE THAT A UNIVERSAL AMBIENT AIR-OXYGEN BLENDER WITH REMOTE MONITORING CAPABILITY AND DELIVERING OXYGEN-ENRICHED AIR OVER A WIDE RANGE OF FIO2 WILL ENABLE A BUBBLE-CPAP DEVICE TO BE PORTABLE, WHILE ALSO FUNCTIONING EFFECTIVELY WITH COMMERCIALLY-AVAILABLE CPAP DEVICES. AS OUR PILOT DATA SHOW, THE PERCENTAGE OF OXYGEN CAN BE VARIED OVER A WIDE RANGE OF FIO2 IN A CONTROLLED MANNER AT CLINICALLY RELEVANT FLOW RATES. WE USED THIS DATA TO INVENT A UNIVERSAL AMBIENT AIR-OXYGEN BLENDER EQUIPPED WITH A DOWNSTREAM FIO2 SENSOR AND FLOW RATE GAUGE, ALLOWING THE HEALTHCARE PROVIDER TO CONTROL FIO2 AND FLOW RATES, REGARDLESS OF THE CPAP TO WHICH IT IS CONNECTED. THE SPECIFIC AIMS ARE: FIRST, TO TEST THE HYPOTHESIS THAT A UNIVERSAL AMBIENT AIR-OXYGEN BLENDER WITH REMOTE MONITORING CAPABILITY WILL ENABLE A BUBBLE-CPAP DEVICE TO BE PORTABLE BY DESIGNING, FABRICATING AND TESTING A PROTOTYPE BUBBLE-CPAP DEVICE; SECOND, TO TEST THE HYPOTHESIS THAT THE AMBIENT AIR- OXYGEN BLENDER WILL FUNCTIONING EFFECTIVELY WHEN THE MODULE IS INTEGRATED WITH COMMERCIALLY-AVAILABLE CPAP SYSTEMS THAT CURRENTLY RELY ON BOTH MEDICAL GRADE OXYGEN AND AIR TANKS. SUCCESSFUL COMPLETION OF THIS PROJECT WILL PROVIDE A PORTABLE CPAP DEVICE FOR TRANSPORT AS WELL AS HOSPITAL BED USE, ALLOW INTEGRATION OF AN AMBIENT AIR-OXYGEN BLENDER WITH OTHER CPAP DEVICES MAKING IT UNNECESSARY TO IMPROVISE DEVICES TO DELIVER 100% OXYGEN THAT CAN CAUSE ORGAN DAMAGE AND ENABLE REMOTE MONITORING TO ENSURE SMOOTH FUNCTIONING OF THE DEVICE.

Posted 8/22/22, 12:00 AM